In a clinical study in 57 newly diagnosed acute myeloid leukemias, low BCL-2 expression levels predicted longer Progression-Free Survival (PFS) (p = 0.02) and longer overall survival (p = 0.06) [125]. The gene discussed is BCL2; the disease is acute myeloid leukemia.